Additional further investigation targeting PLK1 and USP7 would be interested in platinum-resistant lung cancer for clinical usage since platinum-based agents are also first in line for the treatment of NSCLC [40,41,42]. Here, PLK1 is linked to non-small cell lung carcinoma.